ClinicalTrials.gg
CompletedNCT05670704Updated Aug 23, 2024

A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-119 in Healthy Participants

A Phase 1 interventional study of ARGX-119 and Placebo in Healthy Volunteers, sponsored by argenx. Completed at 1 site in Netherlands. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-23.

Sponsored by argenx · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This phase 1 study is an FIH, double-blinded, placebo-controlled study investigating the safety, tolerability, PK, and immunogenicity of ARGX 119 administered as single doses (IV or SC) or multiple doses (IV) to healthy participants. The study IMPs are ARGX-119 or placebo for IV or SC administration.

This study will include 2 parts:

  • In part A, ARGX-119 IV (or placebo IV) will be administered to 9 cohorts as single doses , while ARGX-119 SC (or placebo SC) will be administered to a 10th cohort.
  • In part B, 4 once-weekly IV doses of ARGX-119 (or placebo IV) will be administered in up to 5 cohorts.
02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has reached the age of consent at the time of signing the form and ≤65 years of age
  • Is capable of providing signed informed consent and understands and is capable of complying with protocol requirements
  • Is a healthy participant, defined as having no abnormalities identified in any of the following assessments before the first IMP administration on day 1: medical history, physical examination, standard 12-lead , vital sign measurements, and clinical laboratory tests
  • Is either male or female of nonchildbearing potential.
  • Has negative serum pregnancy tests at both screening and on day -1 (female participants)
  • Has a within the range of 18 to 30 kg/m2 and a body weight within the range of 50 to 100 kg (inclusive) before first IMP administration
  • Agree to use measures consistent with local regulations
  • Agrees to discontinue and refrain from using all medications, including nonprescription and prescription medications, for ≥2 weeks before their first IMP administration through the study. The occasional use of paracetamol is allowed upon approval by the investigator.
  • Is a nonsmoker (defined as an individual who has abstained from smoking for ≥3 months before screening) and does not use nicotine-containing products
  • Has a negative drug and alcohol test for amphetamines, barbiturates, benzodiazepines, cannabis, cocaine, opiates, methadone, tricyclic antidepressants, and alcohol at screening and on day -1
  • Has a body temperature of 35.5 °C to 37.6 °C at screening and before their first IMP administration on day 1

Exclusion criteria

Exclusion Criteria:

  • Has a known to any of the components of the IMP, or has a history of a significant allergic reaction to any drug that is considered exclusionary by the investigator
  • Has been given an product within 3 months or 5 half-lives (whichever is longer) before their first IMP administration
  • Has a positive serum test at screening for an active infection with any of the following conditions: that is indicative of an acute or chronic infection, unless associated with a negative HBsAg or negative HBV DNA test, based on HCV antibody assay unless a negative RNA test is available, based on test results
  • Has a positive COVID-19 test result on day -1, if performed.
  • Has a history of any medical or psychiatric condition that, in the opinion of the investigator, is , may confound the result of the study, or may pose additional risks to the participant while taking part in the study
  • Has clinically relevant abnormalities detected on an that are related to either rhythm or conduction
  • Has a clinically meaningful abnormality in any screening test or vital sign measurement before their first IMP administration
  • Has had an event causing significant blood loss (including blood donation >500 mL) or a transfusion of any blood product ≤12 weeks before their first IMP administration
  • Has a history of any of the following: Consuming >21 units of alcoholic beverages per week ≤2 years before screening; Alcoholism or drug, chemical, or substance abuse ≤2 years before screening; Consuming a large quantity (>6 cups a day) of coffee, tea, or equivalent during the 4 week screening period
  • Has any condition that impairs phlebotomy, including (but not limited to) coagulation disorders (hemophilia A, hemophilia B, Von Willebrand disease), clotting factor deficiencies, or any other condition that would increase the risk of hematoma formation
  • Is an investigator, subinvestigator, research assistant, pharmacist, study coordinator, or other staff or relative of study personnel directly involved with the conduct of the study
  • Has any condition or circumstances that, in the opinion of the investigator, may make a participant unlikely or unable to complete the study or comply with study procedures and requirements
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
112 participants (actual)

Study arms

  • Experimental
    ARGX-119

    Patients receiving ARGX-119 IV or SC

    Biological: ARGX-119

  • Placebo comparator
    Placebo

    Patients receiving Placebo IV or SC

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Number of treatment-emergent adverse events (TEAEs)

    Time frame: up to 157 days for part A, 117 days for part B

Secondary outcomes

  1. Pharmacokinetic parameters of ARGX-119: Area Under The Curve (AUC)

    Time frame: up to 157 days for part A, 117 days for part B

  2. Pharmacokinetic parameters of ARGX-119: Maximum serum concentrations (Cmax)

    Time frame: up to 157 days for part A, 117 days for part B

  3. Pharmacokinetic parameters of ARGX-119: Time to reach maximum serum concentrations (Tmax)

    Time frame: up to 157 days for part A, 117 days for part B

  4. Incidence of antidrug antibodies against ARGX-119

    Time frame: up to 157 days for part A, 117 days for part B

07

Study locations

1 site
  • PRA Health Science
    Groningen, 9728, Netherlands
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2023 to primary completion in Aug 2024, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2022
First posted
Jan 4, 2023
StartActual
Feb 21, 2023
Primary completionActual
Aug 8, 2024
CompletionActual
Aug 8, 2024
Last update
Aug 23, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 23, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05670704
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Jan 4, 2023
Start date
Feb 21, 2023
Primary completion
Aug 8, 2024
Completion
Aug 8, 2024
Last update
Aug 23, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adimanebart · Anti-MuSK Agonistic Monoclonal Antibody ARGX-119

Start the discussion